SCHEMBL9786535

SCHEMBL9786535

CCc1cc(C)n(-c2ccccc2)c1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.56
NOTUM Q6P988 2/20 0.56
MEN1 O00255 3/20 0.47
LMNA P02545 3/20 0.47
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 6/20 0.47
NR1H4 Q96RI1 1/20 0.47
MAPT P10636 6/20 0.46
MITF O75030 1/20 0.46
PLA2G1B P04054 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ATG4B Q9Y4P1 1/20 0.46
RAB9A P51151 7/20 0.46
CNR2 P34972 3/20 0.46
CNR1 P21554 2/20 0.46
KDM4E B2RXH2 1/20 0.45
TP53 P04637 3/20 0.44
RXFP1 Q9HBX9 1/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9786546 0.85 NOTUM (0.54) ALDH1A1NOTUMMEN1LMNAKMT2A
SCHEMBL9786552 0.80 PTGS2 (0.56) TSHR
SCHEMBL11331314 0.80 NR1H4 (0.72) ALDH1A1NOTUMMEN1LMNAKMT2A
SCHEMBL11335546 0.77 NR1H4 (0.54) ALDH1A1NOTUMMEN1KMT2ASMN1; SMN2
SCHEMBL13754330 0.77 NOTUM (0.63) ALDH1A1NOTUMLMNASMN1; SMN2MAPT
SCHEMBL11342404 0.76 RAB9A (0.48) ALDH1A1NOTUMMEN1LMNAKMT2A
SCHEMBL9016307 0.76 SMN1; SMN2 (0.43) ALDH1A1NOTUMMEN1LMNAKMT2A
SCHEMBL5857932 0.75 ALDH1A1 (0.58) ALDH1A1NOTUMMEN1LMNAKMT2A
SCHEMBL23566220 0.75 CNR2 (0.48) ALDH1A1NOTUMMEN1LMNAKMT2A
SCHEMBL14226118 0.74 ALDH1A1 (0.71) ALDH1A1NOTUMLMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7524841-B2 4,4-disubstituted piperidine derivatives having CCR3 antagonism TEIJIN LIMITED (JP) 2009-04-28 US disclosed
US-7524841-B2 4,4-disubstituted piperidine derivatives having CCR3 antagonism TEIJIN LIMITED (JP) 2009-04-28 US disclosed
US-7517875-B2 Piperidine derivatives having CCR3 antagonism TEIJIN LIMITED (JP) 2009-04-14 US disclosed
US-7517875-B2 Piperidine derivatives having CCR3 antagonism TEIJIN LIMITED (JP) 2009-04-14 US disclosed
US-20070037851-A1 Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) 2007-02-15 US disclosed
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) 2007-02-08 US disclosed
US-4992347-A Marking COURTAULDS PLC (GB) 1991-02-12 US disclosed
EP-0190016-B1 PHOTOCHROMIC 3-PYRRYL FULGIDES & FULGIMIDES GEC-MARCONI LIMITED (GB) 1990-11-28 EP disclosed
EP-0390869-A4 ORGANIC PHOTOCHROMIC PIGMENT 1990-11-07 EP disclosed
EP-0390869-A1 ORGANIC PHOTOCHROMIC PIGMENT PPG INDUSTRIES, INC. (US) 1990-10-10 EP disclosed
US-4931220-A EMULSION POLYMERIZATION OF POLYFUNCTIONAL ACRYLATE MIXED WITH PIGMENT; POWDERS PPG INDUSTRIES, INC. (US) 1990-06-05 US disclosed
WO-1989005464-A1 ORGANIC PHOTOCHROMIC PIGMENT PPG INDUSTRIES, INC. (US) 1989-06-15 WO disclosed
EP-0279600-A1 Marking COURTAULDS PLC (GB) 1988-08-24 EP disclosed
EP-0190016-A2 Photochromic 3-pyrryl fulgides & fulgimides GEC-MARCONI LIMITED (GB) 1986-08-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism CCR3, CCR1, CCR4 ALDH1A1 451/4885NOTUM 2644/4885MEN1 3556/4885
US-20070037851-A1 Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells CCR3, CCR1, CCR4 ALDH1A1 486/4885NOTUM 3102/4885MEN1 4549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.